RN7SL1 RNA shown to activate T cells to fight against cancer
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
List view / Grid view
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.
Researchers have created a new method to quantify protein droplets involved in neurodegenerative diseases, enhancing the study of treatments.
Frameshifting therapy has been shown to reduce the number of mast cells by “mutating” mRNA, showing promise as a new cancer treatment.
New insights into lung squamous cell carcinoma (LSCC) have emerged from a proteogenomic study, leading to the identification of potential drug targets.
In this interview, read about the compilation of a new high-resolution cell atlas of the mouse brain using spatial genomics and transcriptomics.
Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
In cell cultures, a compound named STM2457 was shown to interfere with coronavirus replication, making it a potential treatment for SARS-CoV-2.